Trials / Not Yet Recruiting
Not Yet RecruitingNCT06297213
R-2487 in Patients With Sjogren's Syndrome (SS)
A Single and Repeat Dosing Study of the Safety, Drug Exposure and Clinical Activity of R-2487 in Patients With Sjogren's Syndrome (SS)
- Status
- Not Yet Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 36 (estimated)
- Sponsor
- Rise Therapeutics LLC · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this study is to determine the safety and tolerability of orally taken probiotic (R-2487) in patients with Sjogren's Syndrome. Patients will take an oral dosage of probiotic (R-2487) and physicians will assess and measure their Sjogren's Syndrome. Blood and fecal evaluations of inflammation and assessment of probiotic (R-2487) on fecal level will also be measured.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | R-2487 | R-2487 DP |
Timeline
- Start date
- 2026-06-01
- Primary completion
- 2028-08-30
- Completion
- 2028-08-30
- First posted
- 2024-03-07
- Last updated
- 2025-09-04
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06297213. Inclusion in this directory is not an endorsement.